Development and external validation of a plasma metabolomic signature for predicting 3-year all-cause mortality in older adults with CAD
Nutrition, Metabolism and Cardiovascular Diseases · 2026
DOI: 10.1016/j.numecd.2026.104604 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026. Verfasst von Jianhua Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China; Shandong Provincial Clinical Research Center for Emergency and …. Hauptthemen laut MEDLINE: Coronary Artery Disease, Metabolomics. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Taishan Scholar Foundation of Shandong Province.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND AND AIMS: Prognostic stratification in older adults with coronary artery disease (CAD) remains challenging, and existing clinical risk scores have limitations in this population. We aimed to identify and validate a novel plasma metabolomic signature for 3-year all-cause mortality and assess its incremental value over established clinical risk factors. METHODS AND RESULTS: We performed a secondary analysis of data from two temporally distinct, prospectively collected cohorts from the Emory Cardiovascular Biobank (training: n = 269; validation: n = 190). The primary endpoint was 3-year all-cause mortality. A stability-based LASSO algorithm with permutation testing was used to select a robust prognostic signature from 1150 harmonized metabolomic features. The performance of a pre-specified Cox proportional hazards model was assessed for discrimination and calibration in the independent validation cohort. Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) were calculated to quantify added prognostic value over a clinical risk model. A robust 11-metabolite signature was identified. In the independent validation cohort, the pre-specified Cox model demonstrated strong discrimination for 3-year mortality (time-dependent AUC: 0.716; 95% CI: 0.630-0.802) and good calibration. Compared to a model with established clinical risk factors alone, the addition of the 11-metabolite signature resulted in a significant improvement in risk reclassification (NRI: 0.322, 95% CI: 0.190-0.447; IDI: 0.199, 95% CI: 0.127-0.283; both p < 0.001). CONCLUSION: A validated 11-metabolite signature improves long-term mortality risk stratification in older adults with CAD beyond established clinical measures, providing a basis for a new blood-based prognostic tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China; Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medic…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Taishan Scholar Foundation of Shandong Province
- China Postdoctoral Science Foundation
Zitieren
APA
Gu, J., Gao, L., Li, J., Wu, S., & Chen, Y. (2026). Development and external validation of a plasma metabolomic signature for predicting 3-year all-cause mortality in older adults with CAD. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2026.104604
Vancouver
Gu J, Gao L, Li J, Wu S, Chen Y. Development and external validation of a plasma metabolomic signature for predicting 3-year all-cause mortality in older adults with CAD. Nutrition, Metabolism and Cardiovascular Diseases. 2026. doi:10.1016/j.numecd.2026.104604
BibTeX
@article{Gu2026,
author = {Gu, Jianhua and Gao, Luyao and Li, Jiqing and Wu, Shuo and Chen, Yuguo},
title = {Development and external validation of a plasma metabolomic signature for predicting 3-year all-cause mortality in older adults with CAD},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.numecd.2026.104604}
}
EUVIMED